Amphotericin Alone or in Combination With Fluconazole for AIDS-Associated Meningitis
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00145249 |
Recruitment Status
:
Completed
First Posted
: September 5, 2005
Results First Posted
: June 23, 2010
Last Update Posted
: May 16, 2012
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Cryptococcal Meningitis | Drug: Amphotericin B Drug: Fluconazole | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 143 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase II Randomized Trial of Amphotericin B Alone or Combined With Fluconazole in the Treatment of AIDS-Associated Cryptococcal Meningitis |
Study Start Date : | May 2005 |
Actual Primary Completion Date : | April 2008 |
Actual Study Completion Date : | April 2008 |

Arm | Intervention/treatment |
---|---|
Active Comparator: Standard Therapy
Amphotericin B 0.7 mg/kg for 14 day followed by fluconazole 400 mg daily for 8 weeks. For subjects in the standard therapy arm whose Amphotericin B dose is continued beyond 14 days, fluconazole initiation will be delayed.
|
Drug: Amphotericin B
Amphotericin B 0.7 mg/kg IV for the first 14 days of treatment. This period may be extended up to an additional 7 days.
Drug: Fluconazole
Fluconazole 400 or 800 mg daily. Among subjects whose baseline weight is less than 40 kg, randomized fluconazole doses will be 200 mg/kg daily or 400 mg/kg daily.
|
Experimental: Fluconazole Low Dose
Amphotericin B 0.7 mg/kg and the randomized dose of fluconazole at 400 mg/day for the first 14 days, then the randomized dose of fluconazole at 400 mg/day respectively for an additional 8 weeks.
|
Drug: Amphotericin B
Amphotericin B 0.7 mg/kg IV for the first 14 days of treatment. This period may be extended up to an additional 7 days.
Drug: Fluconazole
Fluconazole 400 or 800 mg daily. Among subjects whose baseline weight is less than 40 kg, randomized fluconazole doses will be 200 mg/kg daily or 400 mg/kg daily.
|
Experimental: Fluconazole High Dose
Amphotericin B 0.7 mg/kg and the randomized dose of fluconazole at 800 mg/day for the first 14 days, then the randomized dose of fluconazole at 800 mg/day respectively for an additional 8 weeks.
|
Drug: Amphotericin B
Amphotericin B 0.7 mg/kg IV for the first 14 days of treatment. This period may be extended up to an additional 7 days.
Drug: Fluconazole
Fluconazole 400 or 800 mg daily. Among subjects whose baseline weight is less than 40 kg, randomized fluconazole doses will be 200 mg/kg daily or 400 mg/kg daily.
|
- Number of Grade 3-5 Adverse Experiences That Are Definitely or Probably Related to Study Drug [ Time Frame: Day 100 ]
Events are reported by MedDRA Preferred Term.
Grade 3 - Severe. Incapacitating; inability to perform usual activities and daily tasks; significantly affects clinical status; requires therapeutic intervention.
Grade 4 - Life-threatening. AE is life-threatening.
Grade 5 - Death. AE causes death.
- Number of Dose-limiting Toxicities Attributed to Treatment Regimens [ Time Frame: Day 100 ]
Events are reported by MedDRA Preferred Term.
Dose limiting toxicities include events that resulted in study drug being adjusted, interrupted, or discontinued.
- Number of Deaths [ Time Frame: 14, 42, and 70 days ]
Number of deaths occurring on study.
Day = Day relative to the first dose of study drug.
- Number of Subjects With Cerebrospinal Fluid (CSF) Culture Conversion at Multiple Time Points [ Time Frame: Baseline, 14, 42, and 70 days ]Number of subjects that have a negative fungal culture at Baseline, Day 14, Day 42, and Day 70.
- Number of Subjects Meeting the Key Efficacy Endpoint of Treatment Success [ Time Frame: 14, 42, and 70 days ]Treatment success is defined as a composite of the 3 mycologic and clinical measures: CSF culture conversion; neurologically stable or improved; and alive
- Number of Subjects Reporting Immune Reconstitution Inflammatory Syndrome (IRIS) [ Time Frame: 14, 42, and 70 days ]
Number of subjects reporting immune reconstitution inflammatory syndrome (IRIS) following treatment.
Day = Day relative to first dose of study drug
- Mean Days of Hospitalization [ Time Frame: 7, 14, 42, and 70 days ]Mean days of hospitalization. Includes days subject was hospitalized prior to study enrollment for current hospital stay.
- Number of Cryptococcal Isolates With Antifungal Susceptibility [ Time Frame: Days 14 and 70 ]Isolates were collected at days 14 and 70 for assessment of antifungal susceptibility.
- Mean Change in Neurological Exam Score From Baseline - Day 14 [ Time Frame: Baseline and Day 14 ]Neurological assessment by Mini-mental Status Exam (MMSE). This is collected as a continuous variable with values from 0-30; where lower scores indicate greater impairment.
- Mean Change in Neurological Exam Score From Baseline - Day 42 [ Time Frame: Baseline and Day 42 ]Neurological assessment by Mini-mental Status Exam (MMSE). This is collected as a continuous variable with values from 0-30; where lower scores indicate greater impairment.
- Mean Change in Neurological Exam Score From Baseline - Day 70 [ Time Frame: Baseline and Day 70 ]Neurological assessment by Mini-mental Status Exam (MMSE). This is collected as a continuous variable with values from 0-30; where lower scores indicate greater impairment.
- Mean Change in Neurological Exam Score From Baseline - Day 168 [ Time Frame: Baseline and Day 168 ]Neurological assessment by Mini-mental Status Exam (MMSE). This is collected as a continuous variable with values from 0-30; where lower scores indicate greater impairment.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 13 Years and older (Child, Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- First episode of cryptococcal meningitis as evidenced by a positive cerebrospinal fluid (CSF) stain or cryptococcal antigen, CSF culture pending
- Documentation of proven diagnosis of HIV-1 infection by acceptable labs at any time in the past: this testing includes Enzyme-linked immunosorbent assay (ELISA) or approved rapid testing method with confirmation by Western blot, a second positive ELISA, a positive HIV antigen, or HIV RNA detection.
OR
-Presumptive diagnosis of HIV-1 by approved rapid testing method at screening. This testing must be confirmed by a second ELISA (or Western blot), a positive HIV antigen, or HIV RNA detection within 10 days of study entry.
OR
- Presumptive HIV+. If serologic testing is not available, a history of an AIDS-defining illness (Category C, CDC, 1993) or any of the following conditions: extrapulmonary Pneumocystis carinii disease; multi-dermatomal herpes zoster (>10 lesions in a non-contiguous site); American trypanosomiasis (Chagas disease) of the CNS; Penicillium marneffei disease; visceral leishmaniasis; non-Hodgkin's lymphoma of any cell-type; Hodgkin's lymphoma; bartonellosis; microsporidiosis (>1 month's duration); nocardiosis; invasive aspergillosis; or Rhodococcus equi disease. Confirmation of HIV infection by lab testing, i.e., ELISA or approved rapid testing method with confirmation by Western blot, a second positive ELISA, a positive HIV antigen, or HIV RNA detection must be performed within 10 days of study entry.
- Subjects who are 13 years of age or greater.
- Baseline electrocardiogram (ECG) with QTc interval less than or equal to 500 milliseconds as determined by use of Fredericia's Correction formula.
- Ability of subject or legally authorized representative to give informed consent. For subjects who are unable to provide informed consent, sites will follow their own individual Institutional Review Board (IRB) policy regarding the informed consent process.
Exclusion Criteria:
- Pregnancy. Urine or serum testing must be performed at study entry or within the 7 days prior to study entry.
- Women of childbearing potential unwilling to use a medically approved and highly effective form of birth control while on study drug and for 2 weeks after last dose. Acceptable forms of birth control include an intrauterine device (IUD), oral contraceptives, condoms, abstinence, injectable contraceptive, or any other highly effective means of birth control. (A highly effective method of birth control is defined as those which result in a low failure rate [i.e. less than 1 percent per year] when used consistently and correctly.) Emergency contraceptive treatment and coitus interruptus are not considered effective forms of contraception.
- Breastfeeding.
- A concurrent central nervous system (CNS) process that in the opinion of the investigator would interfere with assessment of response, such as lymphoma, toxoplasmosis, or tuberculosis.
- Other conditions that in the opinion of the investigator would jeopardize the safety of a subject participating in the study or would render the subject unable to comply with the study plan, such as homelessness or IV drug use.
- Estimated creatinine clearance of less than 50 mL/min. NOTE: Testing must be performed at study entry or within the 7 days prior to study entry.
- Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) greater than 5x the upper limit of normal or bilirubin greater than 2.5 x the upper limit of normal. Results from tests performed within the 7 days prior to study entry may be used.
- Known intolerance of or allergy to fluconazole or amphotericin B.
- Subjects unlikely to survive for 2 weeks.
- Coma.
- More than 3 days of any systemic antifungal therapy for this fungal infection, or the need for concurrent systemic antifungal therapy, including flucytosine or interferon-g. Subjects taking fluconazole at less than or equal to 200 mg/day for prophylaxis are not excluded.
- Inability to take oral medications.
- Subjects who have received the following drugs within 7 days of study enrollment: rifampin, rifamycin, rifabutin, phenytoin, carbamazepine, cyclosporin A, tacrolimus, sirolimus, or long-acting barbiturates.
- Subjects who are receiving nevirapine at baseline.
- Strong clinical suspicion of untreated active tuberculosis. (Patients on anti-TB therapy not including rifampin or rifamycin may be eligible.)
- Previous participation in this study or ongoing participation in another trial with an investigational drug.
- Prior case of cryptococcosis with diagnosed central nervous system involvement.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00145249
United States, Alabama | |
University of Alabama at Birmingham | |
Birmingham, Alabama, United States, 35255 | |
United States, California | |
University of Southern California | |
Los Angeles, California, United States, 90033 | |
Harbor-UCLA Medical Center | |
Los Angeles, California, United States, 90502 | |
United States, Colorado | |
University of Colorado | |
Denver, Colorado, United States, 80291-0238 | |
United States, Florida | |
University of Florida | |
Gainesville, Florida, United States, 32610 | |
University of Miami | |
Miami, Florida, United States, 33136-1096 | |
United States, Louisiana | |
Tulane University Health Sciences Center | |
New Orleans, Louisiana, United States, 70112 | |
United States, Michigan | |
Harper University Hospital | |
Detroit, Michigan, United States, 48201 | |
United States, Texas | |
Texas Medical Center - Michael E. DeBakey Veterans Affairs | |
Houston, Texas, United States, 77030 | |
The University of Texas Health Science Center at Houston | |
Houston, Texas, United States, 77030 | |
Thailand | |
Ramathibodi Hospital, Mahidol University | |
Bangkok, Thailand, 10400 | |
Mahidol University - Siriraj Hospital - Medicine | |
Bangkok, Thailand, 10700 | |
Chiang Mai University | |
Chiang Mai, Thailand, 50200 | |
Khon Kaen University | |
Khon Kaen, Thailand, 40002 | |
Bamrasnaradura Institution | |
Nonthaburi, Thailand, 11000 |
Publications of Results:
Responsible Party: | National Institute of Allergy and Infectious Diseases (NIAID) |
ClinicalTrials.gov Identifier: | NCT00145249 History of Changes |
Other Study ID Numbers: |
03-154 BAMSG 3-01 |
First Posted: | September 5, 2005 Key Record Dates |
Results First Posted: | June 23, 2010 |
Last Update Posted: | May 16, 2012 |
Last Verified: | October 2009 |
Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):
Bacterial infections, HIV infection, cryptococcal meningitis |
Additional relevant MeSH terms:
Meningitis Meningitis, Cryptococcal Central Nervous System Diseases Nervous System Diseases Meningitis, Fungal Central Nervous System Fungal Infections Mycoses Cryptococcosis Central Nervous System Infections Fluconazole Amphotericin B Liposomal amphotericin B Antifungal Agents Anti-Infective Agents |
14-alpha Demethylase Inhibitors Cytochrome P-450 Enzyme Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Steroid Synthesis Inhibitors Hormone Antagonists Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Cytochrome P-450 CYP2C9 Inhibitors Cytochrome P-450 CYP2C19 Inhibitors Amebicides Antiprotozoal Agents Antiparasitic Agents Anti-Bacterial Agents |